6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial – The Lancet (free)
Commentaries: Is the duration of adjuvant trastuzumab debate still clinically relevant? – The Lancet (free) AND 6 months treatment with Herceptin is as good as 12 months for preventing breast cancer return – University of Warwick (free)
Join our WhatsApp group
Free Updates in All Specialties!
A daily update on the latest medical news, practice-changing trials and guidelines
TOP 10 Medical News Stories